PI-103 is primarily used in research settings as a potent inhibitor of PI3K (phosphoinositide 3-kinase) and mTOR (mammalian target of rapamycin) signaling pathways. Its application is significant in studying cancer biology, as these pathways are often dysregulated in various cancers, contributing to tumor growth and survival. By inhibiting these pathways, PI-103 helps researchers understand the mechanisms of cancer progression and evaluate potential therapeutic strategies. Additionally, it is utilized in preclinical studies to assess the efficacy of targeting PI3K/mTOR in reducing tumor proliferation and enhancing the effects of other anticancer treatments. Its role in cellular and molecular biology research also extends to exploring metabolic regulation, cell survival, and autophagy processes.